Page 121 - Read Online

Page 10 of 11 Muñoz-Martínez et al. Hepatoma Res 2022;8:30 https://dx.doi.org/10.20517/2394-5079.2022.22

review. J Hepatol 2012;56:1181-8. DOI PubMed
16. Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: Epidemiology and risk factors. Liver Int 2019;39 Suppl 1:19-31. DOI PubMed
17. Boberg KM, Bergquist A, Mitchell S, et al. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical
presentation. Scand J Gastroenterol 2002;37:1205-11. DOI PubMed
18. Villard C, Friis-Liby I, Nilsson E, et al. Population-based prospective surveillance of patients with primary sclerosing cholangitis
(PSC) for early detection of cholangiocarcinoma. Hepatology 2021;74:91A-92A. DOI
19. Ali AH, Tabibian JH, Nasser-Ghodsi N, et al. Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis.
Hepatology 2018;67:2338-51. DOI PubMed
20. Bowlus CL, Lim JK, Lindor KD. AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients With Primary
Sclerosing Cholangitis: Expert Review. Clin Gastroenterol Hepatol 2019;17:2416-22. DOI PubMed
21. Rizvi S, Eaton JE, Gores GJ. Primary Sclerosing Cholangitis as a Premalignant Biliary Tract Disease: Surveillance and Management.
Clin Gastroenterol Hepatol 2015;13:2152-65. DOI PubMed PMC
22. Eaton JE, Welle CL, Bakhshi Z, et al. Early Cholangiocarcinoma Detection With Magnetic Resonance Imaging Versus Ultrasound in
Primary Sclerosing Cholangitis. Hepatology 2021;73:1868-81. DOI PubMed PMC
23. Satiya J, Mousa OY, Gupta K, et al. Diagnostic yield of magnetic resonance imaging for cholangiocarcinoma in primary sclerosing
cholangitis: a meta-analysis. Clin Exp Hepatol 2020;6:35-41. DOI PubMed PMC
24. Venkatesh SK, Welle CL, Miller FH, et al; IPSCSG. Reporting standards for primary sclerosing cholangitis using MRI and MR
cholangiopancreatography: guidelines from MR Working Group of the International Primary Sclerosing Cholangitis Study Group. Eur
Radiol 2022;32:923-37. DOI PubMed
25. Schramm C, Eaton J, Ringe KI, Venkatesh S, Yamamura J; MRI working group of the IPSCSG. Recommendations on the use of
magnetic resonance imaging in PSC-A position statement from the International PSC Study Group. Hepatology 2017;66:1675-88.
DOI
26. Khoshpouri P, Habibabadi RR, Hazhirkarzar B, et al. Imaging Features of Primary Sclerosing Cholangitis: From Diagnosis to Liver
Transplant Follow-up. Radiographics 2019;39:1938-64. DOI PubMed
27. Chapman MH, Webster GJ, Bannoo S, Johnson GJ, Wittmann J, Pereira SP. Cholangiocarcinoma and dominant strictures in patients
with primary sclerosing cholangitis: a 25-year single-centre experience. Eur J Gastroenterol Hepatol 2012;24:1051-8. DOI PubMed
PMC
28. Rudolph G, Gotthardt D, Klöters-Plachky P, Kulaksiz H, Rost D, Stiehl A. Influence of dominant bile duct stenoses and biliary
infections on outcome in primary sclerosing cholangitis. J Hepatol 2009;51:149-55. DOI PubMed
29. Janse M, Lamberts LE, Verdonk RC, Weersma RK. IBD is associated with an increase in carcinoma in PSC irrespective of the
presence of dominant bile duct stenosis. J Hepatol 2012;57:473-4; author reply 475. DOI PubMed
30. Eaton JE, Barr Fritcher EG, Gores GJ, et al. Biliary multifocal chromosomal polysomy and cholangiocarcinoma in primary sclerosing
cholangitis. Am J Gastroenterol 2015;110:299-309. DOI PubMed PMC
31. Hilscher MB, Tabibian JH, Carey EJ, Gostout CJ, Lindor KD. Dominant strictures in primary sclerosing cholangitis: A multicenter
survey of clinical definitions and practices. Hepatol Commun 2018;2:836-44. DOI PubMed PMC
32. Charatcharoenwitthaya P, Enders FB, Halling KC, Lindor KD. Utility of serum tumor markers, imaging, and biliary cytology for
detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 2008;48:1106-17. DOI PubMed
33. Lindor KD, Kowdley KV, Harrison ME; American College of Gastroenterology. ACG Clinical Guideline: Primary Sclerosing
Cholangitis. Am J Gastroenterol 2015;110:646-59; quiz 660. DOI PubMed
34. Levy C, Lymp J, Angulo P, Gores GJ, Larusso N, Lindor KD. The value of serum CA 19-9 in predicting cholangiocarcinomas in
patients with primary sclerosing cholangitis. Dig Dis Sci 2005;50:1734-40. DOI PubMed
35. Sinakos E, Saenger AK, Keach J, Kim WR, Lindor KD. Many patients with primary sclerosing cholangitis and increased serum levels
of carbohydrate antigen 19-9 do not have cholangiocarcinoma. Clin Gastroenterol Hepatol 2011;9:434-9.e1. DOI
36. Björnsson E, Kilander A, Olsson R. CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary
sclerosing cholangitis. Liver 1999;19:501-8. DOI PubMed
37. Ramage JK, Donaghy A, Farrant J, Iorns R, Williams R. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary
sclerosing cholangitis. Gastroenterology 1995;108:865-9. DOI PubMed
38. Hultcrantz R, Olsson R, Danielsson Å, et al. A 3-year prospective study on serum tumor markers used for detecting
cholangiocarcinoma in patients with primary sclerosing cholangitis. Journal of Hepatology 1999;30:669-73. DOI PubMed
39. Association for the Study of the Liver. Electronic address: jhepatology@easloffice.eu., European Association for the Study of the
Liver. EASL Clinical Practice Guidelines on Sclerosing Cholangitis. J Hepatol ;2022:S0168-8278(22)00326. DOI
40. Aabakken L, Karlsen TH, Albert J, et al. Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal
Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. Endoscopy 2017;49:588-608.
DOI
41. Gotthardt DN, Rudolph G, Klöters-Plachky P, Kulaksiz H, Stiehl A. Endoscopic dilation of dominant stenoses in primary sclerosing
cholangitis: outcome after long-term treatment. Gastrointest Endosc 2010;71:527-34. DOI PubMed
42. Chapman MH, Thorburn D, Hirschfield GM, et al. British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and
management of primary sclerosing cholangitis. Gut 2019;68:1356-78. DOI PubMed PMC
43. Bhat P, Aabakken L. Role of Endoscopy in Primary Sclerosing Cholangitis. Clin Endosc 2021;54:193-201. DOI PubMed PMC